Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

Amarin is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 26.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, AMRN has moved about 2.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.6%. This means that Amarin is outperforming the sector as a whole this year.

One other Medical stock that has outperformed the sector so far this year is Royalty Pharma (RPRX). The stock is up 56.8% year-to-date.

For Royalty Pharma, the consensus EPS estimate for the current year has increased 5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

To break things down more, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #162 in the Zacks Industry Rank. On average, this group has gained an average of 7.3% so far this year, meaning that AMRN is slightly underperforming its industry in terms of year-to-date returns. Royalty Pharma is also part of the same industry.

Investors interested in the Medical sector may want to keep a close eye on Amarin and Royalty Pharma as they attempt to continue their solid performance.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research